BiomX Inc. Files 8-K/A Amendment
Ticker: PHGE · Form: 8-K/A · Filed: May 30, 2024 · CIK: 1739174
| Field | Detail |
|---|---|
| Company | Biomx Inc. (PHGE) |
| Form Type | 8-K/A |
| Filed Date | May 30, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, financial-statements, exhibits
TL;DR
BiomX filed an amendment to its 8-K, updating financial statements and exhibits.
AI Summary
BiomX Inc. filed an amendment (8-K/A) on May 30, 2024, to its report originally dated March 14, 2024. This amendment pertains to financial statements and exhibits, specifically related to its common stock and warrants. The company was formerly known as Chardan Healthcare Acquisition Corp. before changing its name on April 30, 2018.
Why It Matters
This filing is an amendment to a previous report, indicating a correction or addition to previously disclosed information regarding BiomX Inc.'s financial statements and exhibits.
Risk Assessment
Risk Level: low — This is a routine amendment to a previous filing, not indicating new material events or significant financial changes.
Key Players & Entities
- BiomX Inc. (company) — Registrant
- March 14, 2024 (date) — Date of earliest event reported
- May 30, 2024 (date) — Filing date of amendment
- Chardan Healthcare Acquisition Corp. (company) — Former company name
- April 30, 2018 (date) — Date of name change
FAQ
What is the purpose of this 8-K/A filing?
This filing is an amendment to a previous Form 8-K, specifically addressing financial statements and exhibits.
When was the original report filed or dated?
The earliest event reported in the original filing was March 14, 2024.
What is the filing date of this amendment?
This amendment was filed on May 30, 2024.
What was BiomX Inc. formerly known as?
BiomX Inc. was formerly known as Chardan Healthcare Acquisition Corp.
When did the company change its name?
The company changed its name on April 30, 2018.
Filing Stats: 717 words · 3 min read · ~2 pages · Grade level 10.4 · Accepted 2024-05-30 17:04:16
Key Financial Figures
- $0.0001 — onsisting of one share of Common Stock, $0.0001 par value , and one Warrant entitling t
Filing Documents
- ea0207019-8ka1_biomx.htm (8-K/A) — 36KB
- ea020701901ex23-1_biomx.htm (EX-23.1) — 8KB
- ea020701901ex99-1_biomx.htm (EX-99.1) — 334KB
- ea020701901ex99-2_biomx.htm (EX-99.2) — 99KB
- ex99-1_001.jpg (GRAPHIC) — 8KB
- 0001213900-24-048040.txt ( ) — 775KB
- phge-20240314.xsd (EX-101.SCH) — 4KB
- phge-20240314_def.xml (EX-101.DEF) — 26KB
- phge-20240314_lab.xml (EX-101.LAB) — 36KB
- phge-20240314_pre.xml (EX-101.PRE) — 25KB
- ea0207019-8ka1_biomx_htm.xml (XML) — 7KB
Financial Statements of Business Acquired
Financial Statements of Business Acquired. The audited financial statements of APT as of and for the years ended December 31, 2023 and 2022, together with the report of Ernst & Young LLP, Independent Auditors with respect thereto, are included as Exhibit 99.1 and are incorporated by reference herein. (b) Pro Forma Financial Information. The unaudited pro forma condensed combined statements of operations of the Company as of and for the year ended December 31, 2023 and the three months ended March 31, 2024 are included as Exhibit 99.2 hereto and are incorporated by reference herein. (d) Exhibits. Exhibit Description 23.1 Consent of Ernst & Young LLP, Independent Auditors 99.1 Audited financial 99.2 Unaudited pro forma condensed combined statements of operations of BiomX Inc. as of and for the year ended December 31, 2023 and the three months ended March 31, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL documents) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOMX INC. May 30, 2024 By: /s/ Jonathan Solomon Name: Jonathan Solomon Title: Chief Executive Officer 2